Pilot of Mailing Buprenorphine
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: strategy of mailing buprenorphine.
- Who it may be relevant to
- Registry conditions: Opioid Use Disorder. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Pragmatic Remote Approach to Improve Transitions of Care and Retention in Opioid Use Disorder Treatment
Overview
This pilot study evaluates the feasibility, acceptability, and preliminary effectiveness of mailing buprenorphine to individuals with opioid use disorder (OUD) following medical hospitalization. The intervention aims to improve retention in treatment by overcoming barriers such as transportation and pharmacy access.
Detailed description
This single-center, hybrid type 3 pilot study will enroll 20 medically hospitalized patients with OUD who are initiated on buprenorphine during their inpatient stay. Participants will be discharged with a supply of buprenorphine and enrolled in the MOUD Direct Delivery (MOUDDD) Program, which mails monthly refills directly to their homes. The study will evaluate the feasibility (successful delivery), acceptability (patient-reported measures), and preliminary effectiveness (treatment retention at 1, 3, and 6 months) of mailing buprenorphine. Secondary outcomes include quality of life, adherence, overdose, and healthcare utilization. The intervention leverages existing mail-order pharmacy protocols and aims to inform scalable strategies for improving transitions of care and retention in OUD treatment.
Interventions
- Other strategy of mailing buprenorphine
This study examines the feasibility and preliminary effectiveness of mailing buprenorphine to overcome barriers such as transportation to obtaining buprenorphine from a pharmacy.
Primary outcome measures
- Feasibility (successful receipt) [Time frame: From enrollment to the end of the study at 6 months]
- Successful receipt [Time frame: From enrollment to the end of study at 6 months.]
- Retention in treatment [Time frame: time of study enrollment to end of study at 6 months]
Eligibility criteria
Inclusion criteria
- Age ≥ 18
- English-speaking
- Diagnosed with OUD and initiated on buprenorphine during hospitalization
- Discharging to a South Carolina address with a stable mailbox
- Access to phone or computer
Exclusion criteria
- Active psychosis or suicidal ideation
- Severe medical or neurocognitive impairment
- Pending incarceration
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
United States · 2 centers
- Medical University of South Carolina — Charleston
- Medical University of South Carolina — Charleston
Identifiers
NCT: NCT07421102 · Pro00146867 · K12DA031794